Discovery of Novel NO–Donor Containing hCA II Inhibitors with Retinal Ganglion Cell-Protective Effects for the Efficient Treatment of Glaucoma
Journal of Medicinal Chemistry · 17.12.2025
DOI: 10.1021/acs.jmedchem.5c03033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 17.12.2025. Verfasst von Xin Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical U…. Hauptthemen laut MEDLINE: Glaucoma, Retinal Ganglion Cells, Carbonic Anhydrase Inhibitors, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Liaoning Revitalization Talents Program, Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province.
Abstract (Originalsprache)
Glaucoma-induced blindness primarily results from RGC apoptosis. A medication capable of effectively reducing IOP while simultaneously preventing RGC apoptosis could offer a holistic approach to glaucoma treatment. In this study, novel NO-donor containing hCA II inhibitors were developed to achieve dual functionality: lowering IOP by decreasing aqueous humor production (via hCA II inhibition) and enhancing outflow (via NO release). The experimental results indicated that the dual-target compound A1 outperformed its single-target counterpart and the reference drug brinzolamide in both acute and chronic high IOP models, demonstrating superior IOP-lowering efficacy without notable in vitro or in vivo toxicity. Of particular interest, compound A1 reduced RGC apoptosis through mechanisms involving decreased oxidative stress and the suppression of astrocyte and NLRP3 inflammasome activation. Ocular metabolism studies further clarified the in vivo metabolic pathway of compound A1. With its synergistic antiglaucoma and RGCs-protective effects, compound A1 represents a promising candidate for comprehensive glaucoma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Department of Ophthalmology, Xinqiao Hospital, Army Medical University, Xinqiao Road, Shapingba District, Chongqing 400037, China.
- Department of Ophthalmology, the Fourth Affiliated Hospital of China Medical University, Shenyang 110016, China.
- School of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
ORCID-Profile: Zhuang Hou
Förderung
- Liaoning Revitalization Talents Program
- Natural Science Foundation of Liaoning Province
- Department of Education of Liaoning Province
- National Natural Science Foundation of China
- Shenyang Municipal Bureau of Science and Technology
Zitieren
APA
Wang, X., Dai, J., Han, J., Zhao, Y., Wang, Y., Liu, Z., Guo, M., Yan, Z., Cao, C., Lu, J., Zhao, M., Mou, Y., Hou, Z., Peng, C., & Guo, C. (2025). Discovery of Novel NO–Donor Containing hCA II Inhibitors with Retinal Ganglion Cell-Protective Effects for the Efficient Treatment of Glaucoma. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03033
Vancouver
Wang X, Dai J, Han J, Zhao Y, Wang Y, Liu Z, et al. Discovery of Novel NO–Donor Containing hCA II Inhibitors with Retinal Ganglion Cell-Protective Effects for the Efficient Treatment of Glaucoma. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c03033
BibTeX
@article{Wang2025,
author = {Wang, Xin and Dai, Junshi and Han, Jihong and Zhao, Yixiao and Wang, Yitong and Liu, Zhongyu and Guo, Mengbi and Yan, Zhongzuo and Cao, Chun and Lu, Jia and Zhao, Min and Mou, Yanhua and Hou, Zhuang and Peng, Cheng and Guo, Chun},
title = {Discovery of Novel NO–Donor Containing hCA II Inhibitors with Retinal Ganglion Cell-Protective Effects for the Efficient Treatment of Glaucoma},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c03033}
}
EUVIMED